Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment
(2021) In Clinical Oncology 33(2). p.92-97- Abstract
Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment of patients with neuroendocrine tumours for over two decades. It is not until recently, however, that it has achieved regulatory approval. The currently approved treatment regimen is a one-size-fits-all scheme, i.e. all patients receive a fixed activity of the radiopharmaceutical (177Lu-DOTATATE) and a fixed number of treatment cycles. Several research groups around the world have studied different approaches of further improving on the results of peptide receptor radionuclide therapy, with many promising retrospective and prospective clinical studies having been published over the years. In this overview, we... (More)
Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment of patients with neuroendocrine tumours for over two decades. It is not until recently, however, that it has achieved regulatory approval. The currently approved treatment regimen is a one-size-fits-all scheme, i.e. all patients receive a fixed activity of the radiopharmaceutical (177Lu-DOTATATE) and a fixed number of treatment cycles. Several research groups around the world have studied different approaches of further improving on the results of peptide receptor radionuclide therapy, with many promising retrospective and prospective clinical studies having been published over the years. In this overview, we summarise some of the most promising strategies identified so far.
(Less)
- author
- Sundlöv, A. LU and Sjögreen-Gleisner, K. LU
- organization
- publishing date
- 2021-02-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Lu-DOTATATE, individualised, neuroendocrine tumours, personalised, PRRT, radionuclide therapy
- in
- Clinical Oncology
- volume
- 33
- issue
- 2
- pages
- 6 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85096191768
- pmid:33189510
- ISSN
- 0936-6555
- DOI
- 10.1016/j.clon.2020.10.020
- language
- English
- LU publication?
- yes
- id
- 6d7326ca-137f-4fad-847c-d270c18ef07d
- date added to LUP
- 2020-11-25 09:22:50
- date last changed
- 2024-07-25 05:14:20
@article{6d7326ca-137f-4fad-847c-d270c18ef07d, abstract = {{<p>Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment of patients with neuroendocrine tumours for over two decades. It is not until recently, however, that it has achieved regulatory approval. The currently approved treatment regimen is a one-size-fits-all scheme, i.e. all patients receive a fixed activity of the radiopharmaceutical (<sup>177</sup>Lu-DOTATATE) and a fixed number of treatment cycles. Several research groups around the world have studied different approaches of further improving on the results of peptide receptor radionuclide therapy, with many promising retrospective and prospective clinical studies having been published over the years. In this overview, we summarise some of the most promising strategies identified so far.</p>}}, author = {{Sundlöv, A. and Sjögreen-Gleisner, K.}}, issn = {{0936-6555}}, keywords = {{Lu-DOTATATE; individualised; neuroendocrine tumours; personalised; PRRT; radionuclide therapy}}, language = {{eng}}, month = {{02}}, number = {{2}}, pages = {{92--97}}, publisher = {{Elsevier}}, series = {{Clinical Oncology}}, title = {{Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment}}, url = {{http://dx.doi.org/10.1016/j.clon.2020.10.020}}, doi = {{10.1016/j.clon.2020.10.020}}, volume = {{33}}, year = {{2021}}, }